Clinical Trial Update: Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for ACC-001 in Japanese patients with Alzheimer's disease focusing on safety, tolerability, and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-01-01